Περίληψη:
One hundred and seven previously untreated patients with measurable
metastatic colorectal cancer who were treated with 5-fluorouracil (5FU)
and leucovorin (LV) in two different maximum doses and schedules were
retrospectively analyzed. Group A, 52 pts, was treated with LV 200
mg/m(2)/D IV push, followed by 5FU 700 mg/m(2)/D IV 1 h infusion for 5
D. Cycle was repeated every 21 D. Group B, 55 pts, was treated with LV
500 mg/m(2)/D in a 2 h infusion and 5FU 600 mg/m(2)/D IV bolus at
mid-time of LV infusion, repeated every week for 6 wk followed by 2-wk
rest period. There was no difference in response (A 8%, B 11%). Median
survival for A was 37 (2-131) wk, B was 59 (1-112) wk (P = 0.021), time
to progression for A was 20 (0-131) wk, B 30 (0-102) wk (P = 0.021).
Administered mean dose intensity of LV was 350.8 mg/m(2)/wk in group A
and 405.0 mg/m(2)/wk in group B without any significant difference; that
of 5FU was significantly higher in group A as compared to group B
(1205.3 vs 468.9 mg/m(2)/wk, respectively) (p < 0.0001). This difference
was a consequence of the planned dose intensity for this drug in the two
treatment regimens.
Toxicity was more frequent and intense in group A for mucositis (P <
0.001), fatigue (P < 0.01), and neurotoxicity (P < 0.05), and in group B
for neutropenia (P < 0.001) and nausea-vomiting (P < 0.001).
There were one and four iatrogenic deaths in group A and B patients,
respectively (NS). Although this study was not prospective and
randomized, we can conclude that toxicity was significantly different in
the two groups, with a prevalence of mucositis in group A and
neutropenia in group B and a higher number of iatrogenic deaths in the
latter group. Response rates were the same for the two groups although
survival and time to progression were significantly increased for group
B patients.
Συγγραφείς:
TSAVARIS, N
FOUTZILAS, G
MARKANTONAKIS, P
MYLONAKIS, N and
BACOYANNIS, C
ZISIADIS, A
BASDANIS, G
KARVOUNIS, N and
SOBOLOS, K
KOSMIDIS, P
